Atara Biotherapeutics Financials - Benzinga

Atara Biotherapeutics Inc

ATRANASDAQ

Trade with Public

Trade with Public

$8.61

0.161.89%

At close: Aug 10, 5:00 PM EST

$8.20

-0.41-4.76%

After Hours: 7:02 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Atara Biotherapeutics Financials

Atara Biotherapeutics (ATRA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Atara Biotherapeutics Q1 EPS $(0.29) Beats $(0.41) Estimate, Sales $516.000K Miss $2.850M Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.41) by 27.5 percent. This is a 108.29 percent decrease over earnings of $3.50 per share

Benzinga Newsdesk

PRO
Atara Biotherapeutics Q4 EPS $(0.25) Beats $(0.44) Estimate, Sales $1.595M Miss $2.671M Estimate

Benzinga Newsdesk

PRO
Atara Biotherapeutics Q3 EPS $(0.32) Beats $(0.86) Estimate, Sales $3.453M Beat $1.398M Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.86) by 62.79 percent. This is a 89.08 percent increase over losses of $(2.93) per share

Benzinga Newsdesk

PRO
Atara Biotherapeutics Q2 EPS $0.19 Beats $(0.81) Estimate, Sales $17.57M Beat $5.67M Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $(0.81) by 123.54 percent. This is a 106.13 percent increase over losses of $(3.10) per

Benzinga Newsdesk

PRO
Atara Biotherapeutics Q1 EPS $3.50 Beats $(1.98) Estimate, Sales $98.15M Beat $5.67M Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of $(1.98) by 276.77 percent. This is a 160.87 percent increase over losses of $(5.75) per

Benzinga Newsdesk

PRO
Atara Biotherapeutics Q4 2024 GAAP EPS $(1.19) Beats $(3.58) Estimate, Sales $32.753 Miss $19.148M Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(3.58) by 66.76 percent. This is a 91.5 percent increase over losses of $(14.00) per share

Benzinga Newsdesk